Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01718301
Other study ID # BOC-HIV
Secondary ID 2012-003984-23
Status Completed
Phase Phase 3
First received October 25, 2012
Last updated July 8, 2015
Start date March 2013
Est. completion date June 2015

Study information

Verified date July 2015
Source Fundacion Clinic per a la Recerca Biomédica
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and efficacy of a Response Guided Therapy of boceprevir 800 mg dosed three times a day (TID) orally (PO) in combination with Peginterferon (either alpha 2b or alpha 2a) and Ribavirin in HIV/HCV genotype 1 infected patients that failed to previous HCV therapy.


Recruitment information / eligibility

Status Completed
Enrollment 128
Est. completion date June 2015
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- For inclusion in the study, subjects must have a qualifying regimen defined as peginterferon alfa-2a plus ribavirin or peginterferon alfa-2b plus ribavirin for a minimum of 12 weeks. If a subject has received more than one such regimen, the most recent regimen is considered the qualifying regimen.

- Subject must have previously documented chronic hepatitis C (CHC) genotype 1 infection. Subjects with other or mixed genotypes are not eligible. The HCV-RNA result at the screening visit must confirm genotype 1 infection and be =10,000 IU/mL.

- Subject must have a liver biopsy with histology consistent with CHC and no other etiology and/or Fibroscan assessment. In case of:

1. No cirrhosis. Biopsies and/or Fibroscan must be within 18 months of screening visit.

2. Cirrhosis. No specific length of time would be requested.

- All patients with cirrhosis must have an ultrasound 6 month within of screening visit.

- Patients must be on stable antiretroviral therapy including a CD4 cell count of more than 100 per mm3 and a HIV plasmatic viral load undetectable (it is < 50 copies/mL) for more than 6 months. Antiretroviral therapy must be Raltegravir-based (al least during the last 3 months).

- Subject must be =18 years of age.

- HIV treatment should not contain efavirenz (EFV), nevirapine (NVP), etravirine (ETV), didanosine (ddI), stavudine (d4T), zidovudine (AZT), or HIV protease inhibitors.

- Subject must weight between 40 kg and 125 kg.

- Subject and subject's partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug.

- Subjects must be willing to give written informed consent and by investigator opinion be able to follow the protocol visit design.

Exclusion Criteria:

- Subjects known to be coinfected with hepatitis B virus (HBsAg positive).

- Patients chronically infected with HCV genotype other than 1

- CD4 cell count < 100 cel/mm3.

- Plasma HIV RNA more than 50 copies/mL

- Platelet count less than 80.000 /mm3

- Subjects who required discontinuation of previous interferon or ribavirin regimen for a severe adverse event considered by the investigator to be possibly or probably related to ribavirin and/or interferon.

- Treatment with ribavirin within 90 days and any interferon-alpha within 1 month of Screening.

- Treatment for hepatitis C with any investigational medication. Prior treatments with herbal remedies with known hepatotoxicity are exclusionary.

- Participation in any other clinical trial within 30 days of randomization or intention to participate in another clinical trial during participation in this study.

- History of hemoglobinopathy (e.g., thalassemia) or any other cause of or tendency to hemolysis.

- Evidence of decompensate liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy.

- Diabetic and/or hypertensive subjects with clinically significant ocular examination findings.

- Unstable or untreated pre-existing psychiatric condition.

- Any known pre-existing medical condition that could interfere with the subject's participation in and completion of the study.

- Any current evidence of substance abuse of alcohol or other drugs.

- Subjects receiving opioid agonist substitution therapy but not enrolled in an opiate substitution maintenance program.

Study Design


Intervention

Drug:
boceprevir

Ribavirin

Peginterferon alfa-2a

Peginterferon alfa-2b


Locations

Country Name City State
Spain Hospital Clinic i Provincial de Barcelona Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Anna Cruceta

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Achievement of sustained virological response (SVR) at week 24 The primary efficacy endpoint is the achievement of SVR, defined as undetectable plasma HCV-RNA at Follow-up Week (FW) 24. If a subject is missing FW 24 data and has undetectable HCV-RNA level at FW 12, the subject would be considered an SVR. Week 24
Secondary Achievement of sustained virological response at weeks 2,4,8,12. The proportion of subjects with virological response (eg. undetectable HCV-RNA at Weeks 2, 4, 8, or 12) in subjects who achieve SVR. Weeks 2, 4, 8, 12
Secondary The proportion of subjects with undetectable HCV-RNA at FW 12. The proportion of subjects with undetectable HCV-RNA at FW 12. Week 12
Secondary The proportion of subjects with undetectable HCV-RNA at 72 weeks after randomization. The proportion of subjects with undetectable HCV-RNA at 72 weeks after randomization. Week 72
Secondary Number of adverse events Safety: number of adverse events From baseline to study completion (up to 72 weeks)
Secondary Resistance of HCV after boceprevir (BOC) containing regimen Resistance of HCV after boceprevir containing regimen. Blood samples will be collected at baseline and after HCV virological failure and resistance analysis will be done at the end of the study in a single Center (Hospital ClĂ­nic-Barcelona). whenever resistance occurs during the study (from week 12 until the date the resistance occurs, assessed up to 72 weeks)
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2